[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma.
Nakanishi
Shohei
S
Toranomon Hospital, Nephrology Center.
Fukagawa
Masafumi
M
D000069449:Cinacalcet; D002986:Clinical Trials as Topic; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000188:drug therapy; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D016030:Kidney Transplantation; D009154:Mutation; D009281:Naphthalenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000378:metabolism; D010282:Parathyroid Neoplasms / Q000188:drug therapy; D044169:Receptors, Calcium-Sensing / Q000819:agonists* / Q000235:genetics
D009281:Naphthalenes; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D000069449:Cinacalcet